Pharsight

Glyxambi generic

Glyxambi is an anti-diabetic medication owned by Boehringer Ingelheim. This drug contains active ingredients Empagliflozin and Linagliptin and it was first authorized for market use on 30 January, 2015.

When will Glyxambi generic be available?

Glyxambi's generic versions are possible to be released after 03 October, 2034, as this is the expiry date of the last relevant patent (US11090323*PED).

Glyxambi uses

Glyxambi can be used in various methods of treating type 2 diabetes mellitus. Its effectiveness stems from the administration of Linagliptin in combination with Empagliflozin, with or without insulin, a sulfonylurea or metformin. It can also treat type 2 diabetes mellitus in patients with renal impairment with a once daily administration of 10 mg or 25 mg of Empagliflozin.

Glyxambi patent expiration

Glyxambi holds a total of 22 drug patents, two of which have already expired (US8119648 and US8178541). The last patent for Glyxambi is set to expire on 03 October, 2034 (US11090323*PED and US10258637*PED). Below are the details of the patent:

EPO Oppostions filed on Glyxambi

Litigations filed on Glyxambi

Glyxambi dosage

Want to ask something?